Larimar Therapeutics names John B. Harlow Jr. president and COO
The board's appointment, effective September 29, 2026, comes with a $560,000 base salary, a $35,000 signing bonus, and inducement equity grants.
SEC filing
Latest
31 stories
Yesterday
Roche posts IMpower010 results in resected NSCLC; adds polatuzumab real-world study
Tuesday, September 29
Thursday, September 24
Pfizer recalls dopamine injection lot; two Phase 3 trials remain not yet recruiting
Wednesday, September 16
Pfizer wins Xeljanz label update; registers four new trials across RSV, eczema, sleep apnea
Tuesday, September 15
Legend Biotech names Ingrid Zhang CEO, effective September 15, 2026
Zhang, formerly Novartis International's Chief Commercial Officer, succeeds interim CEO Alan Bash, who returns to lead the CARVYKTI business.
SEC filing
Friday, September 11
Pfizer-linked studies registered: rimegepant chemo trial, HIBA respiratory virus review
Thursday, September 3
Vaxcyte names new chief medical and legal officers, moves up OPUS-1 data timing
Luis Jodar joins as CMO and David McAvoy as CLO as Vaxcyte says VAX-31 Phase 3 topline data will arrive by end of October 2026 instead of the fourth quarter.
SEC filing
Medicus Pharma subsidiary signs co-development deal with Pfizer for antibody-drug conjugate
Medicus Pharma Inc. licensed rights to Pfizer's early clinical-stage asset CD228V, agreeing to pay up to $27 million in near-term fees plus potential milestones exceeding $1 billion.
SEC filing
CIBINQO label updated by FDA; Pfizer's rimegepant China trial and pipeline items still active
Friday, August 28
FDA approves Roivant's LISRAYA for dermatomyositis, launch begins immediately
The once-daily TYK2/JAK1 inhibitor becomes the first targeted therapy approved for the rare autoimmune disease, with commercial availability starting ahead of prior guidance.
SEC filing (2)
Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trials
Thursday, August 27
FDA approves updated Pfizer-BioNTech COVID-19 vaccine targeting XFG variant
The 2026-2027 formula gained approval for older adults and higher-risk younger people, with shipping starting immediately.
SEC filing
Tuesday, August 25
Septerna names Rajiv Patni, M.D. as Chief Medical Officer
The GPCR-focused biotech's board appointed the physician-executive effective August 24, 2026, filling out its clinical leadership team.
SEC filing
Friday, August 21
Arbutus plans up to $230 million Dutch auction tender offer for common shares
The company said it intends to buy back stock at $5.00 to $5.75 per share, funded by cash on hand, with the offer expected to run late August through late September 2026.
SEC filing
FDA approves ZAVZPRET label update; Pfizer registers RSVpreF and prostate cancer studies
Friday, August 14
EMA validates MAA for Pfizer and Valneva's Lyme disease vaccine candidate
The agency will now formally review PF-07307405, backed by Phase 3 VALOR trial results showing more than 70% efficacy.
SEC filing
OPKO Health amends note agreement, issues $125 million in additional senior secured notes
The notes, tied to EirGen Pharma's mazdutide royalty interest from Eli Lilly, mature in 2044 and carry a SOFR-plus-7.5% rate with a 4% floor.
SEC filing
Pfizer posts hemophilia results, opens eczema Phase 3, ends two skin studies early
Wednesday, August 12
Arbutus reaches FDA alignment on imdusiran Phase 2b design, advances Pfizer/BioNTech LNP suits
The company also began collecting on its $950 million Moderna settlement and outlined a plan to return up to $230 million to shareholders, though timing remains unconfirmed.
SEC filing
Monday, August 10
Enanta reports fiscal Q3 2026 results, dosing underway in pediatric RSV trial
Zelicapavir advances in both pediatric and adult RSV programs while Enanta guides cash runway into fiscal 2029.
SEC filing
Agomab proposes Marino Garcia and Dr. Naimish Patel for board seats
Belgium-based Agomab Therapeutics plans to add the two as non-executive directors, pending a shareholder vote in September 2026.
SEC filing
Thursday, August 6
Roivant reports Q1 fiscal 2027 results, pipeline on track across four vants
Roivant said brepocitinib launch prep for dermatomyositis remains on schedule, three trial readouts are due in the second half of 2026, and it holds $3.9 billion in cash and securities.
SEC filing
Tuesday, August 4
Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drug
VEPPANU won FDA approval and was licensed to Rigel Pharmaceuticals, while Arvinas outlined data timelines for three Phase 1 programs and cash runway into second-half 2028.
SEC filing
Pfizer raises 2026 revenue outlook, reports Q2 loss on impairment charges
Pfizer lifted the midpoint of its full-year revenue guidance while reaffirming adjusted EPS guidance, which factors in costs tied to its Innovent Biologics licensing deal.
SEC filing
Rigel adds VEPPANU to portfolio, keeps R289 timeline, raises 2026 revenue guidance
The oncology and hematology company licensed the PROTAC breast cancer drug from Arvinas and Pfizer and expects U.S. launch in mid-August, while its R289 MDS trial stays on track for second-half 2026 dose selection.
SEC filing
Monday, August 3
Ascentage Pharma names new Chief Business Officer and Chief Commercial Officer
The company appointed Dr. Faiçal Miyara as CBO and Jim Ziegler as CCO on August 2, 2026, dividing global deal-making from U.S. and ex-China commercial duties.
SEC filing
Wednesday, July 29
Pfizer registers Phase 3 trials in alopecia areata and chronic migraine; two Phase 1 studies open
Friday, July 24
Pfizer week: AML donor-leukocyte trial posts results; three early trials advance
Thursday, July 16
Arbutus terminates RSV side deal with Genevant, discloses CEO and CFO Moderna bonuses
The same 8-K disclosing new Pfizer/BioNTech suits and the $230M buyback also reveals a terminated RSV agreement and litigation bonuses for Arbutus executives.
SEC filing